Bioton expands thanks to growth hormone sales

In 2008 Bioton's revenues from selling one drug alone - a growth hormone - will reach $60 million. The company declared it will launch even more innovative drugs within the next few years. The total cost of acquiring the Swiss company was estimated at about zł.230 million. Bioton will also have to invest an additional sum of over zł.20 million in concluding research and registration of new pharmaceuticals. "I think this is the most important transaction of Bioton within last year," said Paweł Burzyński from DM BZ WBK. Having a full portfolio of products does not ensure  market success, but Bioton has so far been successful in generating high operational profits. (Parkiet, pp. 1, 3) M.M.